Gabapentin Capsule
Product Images NDC 71335-0073

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-0073). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 01)

A data table titled 'Gabapentin Dosage Based on Renal Function' showing dosing guidelines according to creatinine clearance levels. It lists total daily dose ranges in mg/day, dose regimens in mg for different dosing frequencies (TID, BID, QD), and post-hemodialysis supplemental doses. Additional notes explain dosage adjustments for impaired renal function and a formula to estimate creatinine clearance using the Cockcroft and Gault equation.*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 03)

Table presenting risk by indication for antiepileptic drugs in a pooled analysis. It compares events per 1,000 patients for placebo versus drug groups across epilepsy, psychiatric, other indications, and totals, along with relative risk and risk difference values for additional drug patients with events per 1,000 patients.*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 04)

A table presenting adverse reactions in pooled placebo-controlled trials for gabapentin in postherpetic neuralgia, comparing incidence percentages between gabapentin (N=336) and placebo (N=227) groups. Reactions are categorized by system such as Body as a Whole, Digestive System, Metabolic and Nutritional Disorders, Nervous System, Respiratory System, and Special Senses.*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 05)

A data table titled 'Adverse Reactions in Pooled Placebo-Controlled Add-On Trials In Epilepsy Patients >12 years of age' comparing the percentage of patients experiencing various adverse reactions between Gabapentin (N=543) and Placebo (N=378) groups. The table categorizes reactions by body system including Body As A Whole, Cardiovascular, Digestive System, Nervous System, Respiratory System, Skin and Appendages, Urogenital System, and Special Senses, listing specific adverse reactions with percentages for each group.*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 06)

A data table titled 'Adverse Reactions in a Placebo-Controlled Add-On Trial in Pediatric Epilepsy Patients Age 3 to 12 Years.' The table compares percentages of various adverse reactions between groups treated with Gabapentin (N=119) and placebo (N=128), categorized by body system including Body As A Whole, Digestive System, Nervous System, and Respiratory System.*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 07)

Chemical structure diagram of gabapentin illustrating its molecular formula with a cyclohexane ring, an amino group (CH2NH2), and a carboxyl group (CH2CO2H).*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 08)

A table titled 'Controlled PHN Studies: Duration, Dosages, and Number of Patients' showing data from two studies with columns for Study, Study Duration, Gabapentin Target Dose (mg/day), Patients Receiving Gabapentin, and Patients Receiving Placebo. Study 1 lasted 8 weeks with a 3,600 mg/day dose and 113 patients receiving gabapentin versus 116 placebo. Study 2 lasted 7 weeks with target doses of 1,800 and 2,400 mg/day and 223 patients receiving gabapentin versus 111 placebo. The total patients are 336 for gabapentin and 227 for placebo.*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 09)

A line graph showing mean pain scores over an 8-week period comparing Gabapentin 3600 mg/day to placebo. The x-axis represents weeks from baseline to week 8, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 9. Gabapentin group scores decrease over time, while placebo scores remain relatively stable.*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 10)

A line graph showing the mean pain score over a 7-week period comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks, including a 3-week dose titration period and a 4-week fixed dose period, while the y-axis represents mean pain score from 0 to 10. Both Gabapentin doses show a decrease in mean pain score compared to placebo.*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 11)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing two studies. For Study 1, the graph compares placebo (PBO) at 12% and Gabapentin 3600 mg at 29%. For Study 2, placebo (PBO) is at 14%, Gabapentin 1800 mg at 32%, and Gabapentin 2400 mg at 34%. Statistical significance markers indicate p-values less than 0.01 and 0.001 for Gabapentin doses versus placebo.*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 12)

A scatter plot showing percent difference versus daily dose (mg) for three studies labeled 'STUDY a,' 'STUDY b,' and 'STUDY c.' The x-axis represents daily doses ranging from 600 mg to 1800 mg, and the y-axis represents difference percentage from 2% to 22%. Data points for each study are marked with distinct square symbols in black, gray, and white, respectively.*

FDA Label Image

Label Image (Lbl713350073)

Label for Gabapentin 100 mg capsule by Bryant Ranch Prepack, presenting the generic name and strength prominently. Includes a comparison to Neurontin 100 mg capsules by InvaGen Pharmaceuticals Inc. Displays storage instructions for 20-25°C and warnings to keep out of reach of children. Features lot number, barcode, and NDC 71335-0073.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.